IN192178B - - Google Patents

Info

Publication number
IN192178B
IN192178B IN830DE2001A IN192178B IN 192178 B IN192178 B IN 192178B IN 830DE2001 A IN830DE2001 A IN 830DE2001A IN 192178 B IN192178 B IN 192178B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Yatendra Kumar
Om Dutt Tyagi
Maheshwari Nitin
Original Assignee
Ranbaxy Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab filed Critical Ranbaxy Lab
Priority to IN830DE2001 priority Critical patent/IN192178B/en
Priority to PL02373892A priority patent/PL373892A1/xx
Priority to US10/485,590 priority patent/US7002018B2/en
Priority to JP2003519036A priority patent/JP2005519862A/ja
Priority to PCT/IB2002/003013 priority patent/WO2003014086A1/en
Priority to EA200400263A priority patent/EA200400263A1/ru
Priority to EP02755413A priority patent/EP1417172A4/en
Priority to NO20040485A priority patent/NO20040485L/no
Priority to ZA200401103A priority patent/ZA200401103B/en
Publication of IN192178B publication Critical patent/IN192178B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
IN830DE2001 2001-08-03 2001-08-03 IN192178B (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IN830DE2001 IN192178B (zh) 2001-08-03 2001-08-03
PL02373892A PL373892A1 (en) 2001-08-03 2002-08-02 Process for the preparation of amorphous form of torsemide
US10/485,590 US7002018B2 (en) 2001-08-03 2002-08-02 Process for the preparation of amorphous form of torsemide
JP2003519036A JP2005519862A (ja) 2001-08-03 2002-08-02 無形形態トルセミド製造法
PCT/IB2002/003013 WO2003014086A1 (en) 2001-08-03 2002-08-02 Process for the preparation of amorphous form of torsemide
EA200400263A EA200400263A1 (ru) 2001-08-03 2002-08-02 Способ получения аморфной формы торсемида
EP02755413A EP1417172A4 (en) 2001-08-03 2002-08-02 PROCESS FOR PREPARING AN AMORPH FORM OF TORSEMID
NO20040485A NO20040485L (no) 2001-08-03 2004-02-03 Fremgangsmåte til fremstilling av amorf form av torsemid.
ZA200401103A ZA200401103B (en) 2001-08-03 2004-02-11 Process for the preparation of amorphous form of torsemide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN830DE2001 IN192178B (zh) 2001-08-03 2001-08-03

Publications (1)

Publication Number Publication Date
IN192178B true IN192178B (zh) 2004-03-06

Family

ID=11097098

Family Applications (1)

Application Number Title Priority Date Filing Date
IN830DE2001 IN192178B (zh) 2001-08-03 2001-08-03

Country Status (9)

Country Link
US (1) US7002018B2 (zh)
EP (1) EP1417172A4 (zh)
JP (1) JP2005519862A (zh)
EA (1) EA200400263A1 (zh)
IN (1) IN192178B (zh)
NO (1) NO20040485L (zh)
PL (1) PL373892A1 (zh)
WO (1) WO2003014086A1 (zh)
ZA (1) ZA200401103B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7980900B2 (en) * 2004-05-14 2011-07-19 Commscope, Inc. Of North Carolina Next high frequency improvement by using frequency dependent effective capacitance
WO2013132511A1 (en) * 2012-03-09 2013-09-12 Hetero Research Foundation Novel polymorph of lurasidone hydrochloride
CN103694165B (zh) * 2013-11-12 2016-05-04 江苏正大清江制药有限公司 吉美嘧啶无定形固化物及制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34580A (en) * 1862-03-04 Improvement in brick-machines
US30633A (en) * 1860-11-13 Improvement in fire-escapes
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
CZ2002404A3 (cs) 1999-08-11 2002-06-12 Teva Pharmaceutical Industries Ltd. Polymorfní formy torsemidu
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
HRP20000328A2 (en) 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide

Also Published As

Publication number Publication date
ZA200401103B (en) 2006-04-26
PL373892A1 (en) 2005-09-19
EA200400263A1 (ru) 2005-06-30
US20040254223A1 (en) 2004-12-16
EP1417172A1 (en) 2004-05-12
WO2003014086A1 (en) 2003-02-20
NO20040485L (no) 2004-04-02
JP2005519862A (ja) 2005-07-07
EP1417172A4 (en) 2005-05-11
US7002018B2 (en) 2006-02-21

Similar Documents

Publication Publication Date Title
BE2022C531I2 (zh)
BE2022C547I2 (zh)
BE2017C056I2 (zh)
BE2017C051I2 (zh)
BE2017C032I2 (zh)
BE2016C051I2 (zh)
BE2015C077I2 (zh)
BE2015C046I2 (zh)
BE2014C052I2 (zh)
BE2014C036I2 (zh)
BE2014C026I2 (zh)
BE2017C050I2 (zh)
BE2014C004I2 (zh)
BE2014C006I2 (zh)
FR12C0012I1 (zh)
BE2011C034I2 (zh)
BE2007C047I2 (zh)
AU2002307149A8 (zh)
JP2002217752A5 (zh)
BE2016C021I2 (zh)
BE2014C008I2 (zh)
BRPI0204884A2 (zh)
JP2002216460A5 (zh)
BE2017C059I2 (zh)
JP2002084421A5 (zh)